Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
October 29 2024 - 8:15AM
Business Wire
Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a
social innovation platform dedicated to accelerating promising
health innovations, today announced the appointment of Sylvia
Hermina to its Board of Directors. With over 20 years of experience
advising public companies on corporate governance, mergers and
acquisitions, and shareholder relations, Ms. Hermina brings a
wealth of expertise in fostering effective and impactful engagement
between management teams and stakeholders.
Throughout her career, Ms. Hermina has advised NYSE and NASDAQ
listed companies on governance best practices and developed
communication strategies tailored to retail and institutional
investors. As Senior Vice President at Kingsdale Advisors, she has
spearheaded the firm’s U.S. expansion, led strategic initiatives
for mergers and acquisitions, and provided essential guidance on
shareholder activism preparedness.
“We are thrilled to welcome Sylvia to our Board, especially at
this defining stage,” said Amro Albanna, Co-Founder, Chairman, and
CEO of Aditxt. “As we accelerate our current immune and precision
health missions and expand into women’s health, it is vital to
ensure that women’s perspectives and voices are represented at the
highest level of decision-making. Sylvia’s knowledge and belief of
Aditxt and its mission and extensive governance background will be
an invaluable asset as we continue to scale our business and
accelerate the growth of our programs.”
Ms. Hermina added, “I am delighted to join Aditxt’s Board of
Directors and collaborate with the team to drive the company’s
vision and growth. I look forward to working with the Board and
management to support the breakthroughs that could potentially
change people's lives worldwide while concurrently driving
long-term shareholder value.”
About Aditxt, Inc.
Aditxt, Inc.® is a social innovation platform dedicated to
accelerating promising health innovations. Aditxt’s ecosystem of
research institutions, industry partners, and shareholders
collaboratively drives their mission to "Make Promising Innovations
Possible Together." The innovation platform is the cornerstone of
Aditxt’s strategy, where multiple disciplines drive disruptive
growth and address significant societal challenges. Aditxt operates
a unique model that democratizes innovation, ensures every
stakeholder’s voice is heard and valued and empowers collective
progress.
Aditxt currently operates two programs focused on immune health
and precision health. The Company plans to introduce two additional
programs dedicated to public health and women’s health. For these,
Aditxt has entered into an Arrangement Agreement with Appili
Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which
focuses on infectious diseases, and a Merger Agreement with Evofem
Biosciences, Inc. (OTCQB: EVFM). Each program will be designed to
function autonomously while collectively advancing Aditxt’s mission
of discovering, developing, and deploying innovative health
solutions to tackle some of the most urgent health challenges. The
closing of each of the transactions with Appili and Evofem is
subject to several conditions, including but not limited to
approval of the transactions by the respective target shareholders
and Aditxt raising sufficient capital to fund its obligations at
closing. No assurance can be provided that all of the conditions to
closing will be obtained or satisfied or that either of the
transactions will ultimately close.
For more information, www.aditxt.com.
Follow us on:
LinkedIn: https://www.linkedin.com/company/aditxt Facebook:
https://www.facebook.com/aditxtplatform/
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of federal
securities laws. Forward-looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses, or current expectations concerning, among other things,
the Company’s ongoing and planned product and business development;
the Company’s ability to finance and execute its strategic M&A
initiatives; the Company’s ability to obtain the necessary funding
and partner to commence clinical trials; the Company’s intellectual
property position; the Company’s ability to develop commercial
functions; expectations regarding product launch and revenue; the
Company’s results of operations, cash needs, spending, financial
condition, liquidity, prospects, growth, and strategies; the
Company’s ability to raise additional capital; the industry in
which the Company operates; and the trends that may affect the
industry or the Company. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, as well as market and
other conditions and those risks more fully discussed in the
section titled “Risk Factors” in Aditxt’s most recent Annual Report
on Form 10-K, as well as discussions of potential risks,
uncertainties, and other important factors in the Company’s other
filings with the Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241029446009/en/
Media Relations Contact: Mary O’ Brien mobrien@aditxt.com (516)
753-9933
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Dec 2023 to Dec 2024